Cardiac Rehab Lowers Risk for Death After Coronary Artery Bypass Grafting
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 2, 2023 -- Cardiac rehabilitation (CR) is associated with lower two-year mortality following coronary artery bypass grafting (CABG), according to a study published online June 29 in the Annals of Thoracic Surgery.
Tyler M. Bauer, M.D., from the University of Michigan in Ann Arbor, and colleagues linked Medicare fee-for-service claims to surgical data for 6,412 patients discharged alive after isolated CABG (Jan. 1, 2015, through Sept. 30, 2019). Death within two years of discharge was compared for patients using CR versus those without CR.
The researchers found that 60.0 percent of patients were enrolled in CR for an average of 23.2 sessions, with 12.0 percent completing all recommended 36 sessions. Older age, discharge to home (versus extended care facility), and shorter length of stay were predictors for postdischarge CR use. There was a significant reduction in two-year mortality seen for CR users versus CR nonusers (unadjusted: 9.4 percent reduction; inverse probability treatment weighting: 4.8 percent reduction).
"These data suggest that CR use is associated with lower two-year mortality," the authors write. "Future quality initiatives should consider identifying and addressing root causes of poor CR enrollment and completion."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.